Mazdutide

Concentration: Commonly 5 mg, 10 mg vials (lyophilized powder)

Composition: Synthetic dual agonist peptide (GLP-1R / GCGR)

Formulation: Lyophilized acetate buffered peptide

Half-Life: Extended, designed for weekly research dosing

Primary Actions: Weight loss, glycemic control, liver fat reduction

Shown in studies to reduce body weight and visceral fat.

Explored for improving insulin sensitivity and glucose regulation.

Demonstrated potential for NAFLD and obesity-related research.

Compared with Survodutide and Retatrutide as part of dual agonist class.

Reconstitute with bacteriostatic water (NuroCore standard).

Swirl gently until dissolved fully.

Handle under sterile laboratory conditions.

Unreconstituted: Store at –20 °C.

Reconstituted: Refrigerate at 2–8 °C.

Appearance: Clear, colorless solution; discard if cloudy or particulate.

Category: Metabolic & Weight Management Research (NuroCore)

Use Case: Research into weight loss, insulin sensitivity, and liver fat reduction

Compliance Note: Classified strictly as a research compound